Evaluation of Prognostic Monitoring for Triple Negative Breast Cancer Patients
- Conditions
- Triple Negative Breast Cancer
- Registration Number
- NCT04145947
- Lead Sponsor
- Peking Union Medical College Hospital
- Brief Summary
The relationship between immune inflammation-related protein complexes in blood of triple negative breast cancer patients and recurrence or metastasis of breast cancer will be studied.
- Detailed Description
200 patients with triple negative breast cancer will be followed up. Peripheral venous blood was collected every 3 to 6 months. Change regularity of breast cancer-specific immune inflammation-related protein complexes in blood at different follow-up time points will be studied. The relationship between disease-specific protein complexes and pathological state of patients will be analyzed.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 200
- Female
- Postoperative pathology confirmed invasive breast cancer after surgery for breast lump
- Breast cancer-related chemotherapy and radiotherapy completed
- triple negative breast cancer patients
- age ≤ 60 years old
- Male
- Aged above 60
- Breast Carcinoma in situ
- Women in pregnancy or breastfeeding
- Suffering from other malignant tumors
- Non-compliant patient
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method blood markers 2 years The expression of CA153, CEA, CA125 in the blood of the patients, which are measured by electro-chemiluminescence immunoassay.
immune inflammation-related protein complexes 2 years The change of immune inflammation-related protein complexes which is measured by gel permeation chromatography.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Peking Union Medical College Hospital
🇨🇳Beijing, Beijing, China